Indivior (NASDAQ:INDV) Share Price Breaks Above 50-Day Moving Average – Should You Sell?

Indivior PLC (NASDAQ:INDV) crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $35.24 and traded as high as $37.00. Indivior shares last traded at $35.25, with a volume of 5,718,744 shares.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on INDV. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Barclays upped their price target on Indivior from $43.00 to $45.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Craig Hallum reissued a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $45.50.

Indivior Stock Performance

The firm’s 50-day moving average price is $35.24 and its two-hundred day moving average price is $35.62. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 12.63 and a beta of 0.87.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The firm had revenue of $356.00 million during the quarter, compared to analyst estimates of $329.35 million. As a group, equities research analysts anticipate that Indivior PLC will post 3.66 EPS for the current year.

Indivior Announces Dividend

The business also recently disclosed a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be paid a $8.13 dividend.

Insider Activity

In related news, CAO Woodrow D. Anderson bought 1,500 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was acquired at an average cost of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.74% of the company’s stock.

Institutional Trading of Indivior

A number of large investors have recently bought and sold shares of INDV. HighTower Advisors LLC acquired a new position in Indivior during the second quarter worth $3,409,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Indivior during the second quarter valued at $7,988,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Indivior during the second quarter valued at $3,332,000. Cookson Peirce & Co. Inc. bought a new position in shares of Indivior during the second quarter valued at $1,390,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Indivior in the 2nd quarter valued at $1,870,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.